For instance, a phase 2 study suggested that pembrolizumab combined with chemotherapy demonstrated an ORR of 42%, a median PFS of 8.3 months, and a median OS of 22.2 months among patients with recurrent EGFR-mutated NSCLC (n = 26).38 The gene discussed is EGFR; the disease is non-small cell lung carcinoma.